Moderate-to-severe asthma patients were selected, and their baseline IgE levels were recorded, and the IgE levels were tested again after 4 weeks of treatment with omalizumab to calculate the 4-week IgE/baseline IgE ratio. Here, IGHE is linked to asthma.